Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.
Mode of action and clinical studies with alemtuzumab.
Flare up reaction during provocation test to glatiramer acetate in a patient with allergy to interferon beta1a.
Sulfocerebrosides upregulate liposome uptake in human astrocytes without inducing a proinflammatory response.
Activated Human CD4+CD45RO+ Memory T-Cells Indirectly Inhibit NLRP3 Inflammasome Activation through Downregulation of P2X7R Signalling.
Mouse Models of Multiple Sclerosis: Experimental Autoimmune Encephalomyelitis and Theiler's Virus-Induced Demyelinating Disease.
Multiple sclerosis databases: present and future.
Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab.
Burden of risk variants correlates with phenotype of multiple sclerosis.
Myelin loss and axonal ion channel adaptations associated with gray matter neuronal hyperexcitability.
MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing.
Gray Matter Involvement in Radiologically Isolated Syndrome.
Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease.
Chronic inflammatory demyelinating polyradiculoneuropathy: update on clinical features, phenotypes and treatment options.
Prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: a blinded sonographic evaluation.
Step-rate thresholds for physical activity intensity in persons with multiple sclerosis.
Astrogliosis as a therapeutic target for neurodegenerative diseases.
Beta2-adrenergic agonist use and the risk of multiple sclerosis: a total population-based case-control study.
Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis.
Relationship between contrast sensitivity test and disease severity in multiple sclerosis patients.
MRI Study: Objective Olfactory Function and CNS Pathologies in Patients with Multiple Sclerosis.
Experimental and therapeutic opportunities for stem cells in multiple sclerosis.
Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis.
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis.
Antibodies to MOG in NMO: A seasoned veteran finds a new role.
Pages
« first
‹ previous
…
375
376
377
378
379
380
381
382
383
…
next ›
last »